Littleton, CO, April 23, 2011 --(PR.com
)-- Novus Biologicals is excited to announce a new PINK1 antibody (catalog number NBP1-49678) for the study of mitochondrial markers and neurodegeneration. This PINK 1 antibody was made using SDIX Genomic Antibody TechnologyTM (GATTM).
PTEN-induced putative kinase 1 (PINK1) is a mitochondrial serine/threonine-protein kinase, involved in the PTEN tumor suppression pathway. PINK-1 protects cells from stress-induced mitochondrial dysfunction, and defects in this protein may lead to various cancers and Parkinson’s disease. PINK 1 is strongly expressed in the skeletal muscle, heart and testis, and is expressed at lower levels in the brain, placenta, liver, kidney, pancreas, prostate, ovary and small intestine.
SDIX GAT uses sophisticated bioinformatics and immunization strategies to produce high-quality antibodies that specifically bind to targeted regions of the protein in its naturally folded form. The ability of an antibody to recognize a protein’s naturally folded state enables its utility in high-value applications like sandwich immunoassay, ChIP, and flow cytometry. Learn more about SDIX Genomic Antibodies™ by reading the SDIX Genomic Antibodies FAQ or by downloading the SDIX Genomic Antibodies White Paper.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.
About SDIX (www.sdix.com)
SDIX is a biotechnology company with a core expertise at creating better antigens, better antibodies and better assays for the pharmaceutical, biotechnology and food safety markets. For over 20 years, SDIX has been a leading immuno-solutions Company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives.
In the life science market, SDIX’s technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs, and provide antibodies and assays for the diagnosis of disease. In the food safety market, SDIX continues to expand its footprint as an international supplier of rapid pathogen test technologies that enable more accurate and cost effective results.
This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like “anticipate,” “could,” “enable,” “estimate,” “intend,” “expect,” “believe,” “potential,” “will,” “should,” “project,” “plan” and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.